Log on / register
Feedback | Support | My details
Deciphering cellular states of innate tumor drug responses.
Graudens E, Boulanger V, Mollard C, Mariage-Samson R, Barlet X, Grémy G, Couillault C, Lajémi M, Piatier-Tonneau D, Zaborski P, Eveno E, Auffray C, Imbeaud S
Genome Biol 2006, 7:R19
[Full text] [PubMed] [Related articles] [Cited on BioMed Central]


printer friendly 
to  [Help]

BioMed Central articles that cite the above article:

1.
37%37%


 Research article    
The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome
Butt AJ, Sergio CM, Inman CK, Anderson LR, McNeil CM, Russell AJ, Nousch M, Preiss T, Biankin AV, Sutherland RL, Musgrove EA
Breast Cancer Research 2008, 10:R28 (29 March 2008)
 [Abstract] [Full text] [PDF] [PubMed] [Related articles]
2.
37%37%


 Research    
Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine
Segura-Pacheco B, Perez-Cardenas E, Taja-Chayeb L, Chavez-Blanco A, Revilla-Vazquez A, Benitez-Bribiesca L, Duenas-González A
Journal of Translational Medicine 2006, 4:32 (7 August 2006)
 [Abstract] [Full Text] [PDF] [PubMed] [Related articles]
3.
37%37%


 Hypothesis    
Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy?
Perez-Plasencia C, Duenas-Gonzalez A
Molecular Cancer 2006, 5:27 (10 July 2006)
 [Abstract] [Full Text] [PDF] [PubMed] [Related articles] [Cited on BioMed Central]

This article is also cited by a further 2 articles in PubMed Central


You can also check ISI Web of Science for additional citations (subscription required)
printer friendly 
to  [Help]
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.